Patents Examined by Gollamudi S. Kishore
  • Patent number: 11458199
    Abstract: The present invention relates to pharmaceutical formulations comprising an anti angiogenic compound such as a monoclonal antibody or fragment thereof selected from, for example, ranibizumab, which is a vascular endothelial growth factor binder which inhibits the action of VEGF, and a delivery agent selected from a pharmaceutically acceptable liposome. The formulations are useful in the treatment of a variety of angiogenic disorders and diseases in animals and people, and, preferably, in ophthalmic disorders selected from age-related macular degeneration, diabetic macular edema and corneal neovascularization.
    Type: Grant
    Filed: May 30, 2019
    Date of Patent: October 4, 2022
    Assignee: OPKO Pharmaceuticals, LLC
    Inventors: Arturo Santos, Phillip Frost, Jane Hsiao
  • Patent number: 11452691
    Abstract: Embodiments of the present application relate to compositions of multivesicular liposomes (MVLs) and manufacturing processes for making bupivacaine MVLs.
    Type: Grant
    Filed: May 19, 2022
    Date of Patent: September 27, 2022
    Assignee: Pacira Pharmaceuticals, Inc.
    Inventors: Jeffrey S. Hall, David J. Turnbull, John J. Grigsby, Jr., Soroush M. Ardekani, Kathleen D. A. Los
  • Patent number: 11446247
    Abstract: An object of the present invention is to provide a liposome composition and a pharmaceutical composition, which exhibit a high AUC. Provided are a liposome composition including a hydrophilic polymer-modified diacylphosphatidylethanolamine, a dihydrosphingomyelin, and cholesterols as components of a liposome membrane, in which the liposome composition encapsulates a drug, an inner water phase thereof contains ammonium sulfate, and a molar ratio of sulfate ions in the inner water phase to the drug in an entire water phase is 0.36 or more; and a pharmaceutical composition including the liposome composition.
    Type: Grant
    Filed: October 26, 2020
    Date of Patent: September 20, 2022
    Assignee: FUJIFILM Corporation
    Inventors: Noriyuki Kasagi, Naoki Yamada, Mikinaga Mori, Takayuki Kato, Takayuki Kobayashi
  • Patent number: 11433143
    Abstract: In certain embodiments a platform technology for the facilitating immune therapy in the treatment of cancer is provided. In certain embodiments nanocarriers are provided that facilitate delivery of an IDO inhibitor in conjunction with an inducer of cell death (ICD-inducer). In certain embodiments the IDO inhibitor is conjugated to a component of a lipid bilayer forming a nanovesicle. In still another embodiment, methods and compositions are provided where an ICD-inducing agent (e.g., doxorubicin, oxaliplatin, mitoxantrone etc.) and an IDO pathway inhibitor (e.g., an IDO inhibitor-prodrug) are integrated into a nanocarrier (e.g. a lipid-bilayer (LB)-coated nanoparticle), that allows systemic delivery to orthotopic pancreatic cancer site.
    Type: Grant
    Filed: November 18, 2019
    Date of Patent: September 6, 2022
    Assignee: The Regents of the University of California
    Inventors: Andre E. Nel, Huan Meng, Kuo-Ching Mei
  • Patent number: 11433026
    Abstract: The disclosure provides compositions and methods of use of formulations effective for the delivery of biologically active molecules and materials, including therapeutic and diagnostic agents, and combinations thereof, to cells, tissues, and living organisms. More particularly, the present invention is related to the incorporation of hydrophobic nanoparticles, such as hydrophobic metal nanoparticles, into the membranes of vesicular delivery vehicles. These hydrophobic nanoparticles enhance the endosomal membrane fusogenicity of the formulations through the promotion of inverted hexagonal phase formation in the lipid bilayers of the vesicular delivery vehicles. As a result, the vesicular delivery vehicles more readily fuse with the endosomal membranes, leading to enhanced endosomal escape of the vesicular delivery vehicle and its contents, thereby facilitating the delivery of the biologically active molecules and materials incorporated within the vesicular delivery vehicles to their sites of action.
    Type: Grant
    Filed: April 2, 2018
    Date of Patent: September 6, 2022
    Assignee: University of Rhode Island Board of Trustees
    Inventors: Ashish Sarode, Ruchi Verma, David Worthen, Ruitang Deng
  • Patent number: 11419887
    Abstract: PSA is delivered to the host by outer membrane vesicles (OMVs), secretion structures that target bacterial molecules to host cells. Purified OMVs direct the in vitro differentiation of functional Tregs with potent suppressive activity in a PSA dependent manner. Treatment of animals with OMVs containing PSA prevents experimental colitis and suppresses pro-inflammatory cytokine responses in the gut, and indicate that compositions, medicaments, and methods useful for the treatment of inflammation, and more particularly, inflammatory bowel diseases.
    Type: Grant
    Filed: April 17, 2019
    Date of Patent: August 23, 2022
    Assignee: California Institute of Technology
    Inventors: Yue Shen, Sarkis K. Mazmanian
  • Patent number: 11413244
    Abstract: An object of the present invention is to provide a liposome composition and a pharmaceutical composition, which exhibit a high AUC. Provided are a liposome composition including a hydrophilic polymer-modified diacylphosphatidylethanolamine, a dihydrosphingomyelin, and cholesterols as components of a liposome membrane, in which the liposome composition encapsulates a drug, an inner water phase thereof contains ammonium sulfate, and a molar ratio of sulfate ions in the inner water phase to the drug in an entire water phase is 0.36 or more; and a pharmaceutical composition including the liposome composition.
    Type: Grant
    Filed: September 26, 2019
    Date of Patent: August 16, 2022
    Assignee: FUJIFILM Corporation
    Inventors: Noriyuki Kasagi, Naoki Yamada, Mikinaga Mori, Takayuki Kato, Takayuki Kobayashi
  • Patent number: 11406628
    Abstract: Provided is a sustained-release triptan composition as a suitable depot formulation to carry a therapeutically effective amount of triptan for administration via subcutaneous or intramuscular injection. This sustained-release triptan composition is characterized by a high drug to phospholipid ratio and provides an improved pharmacokinetic profile in vivo. The sustained-release triptan composition is for use as a medicament in the treatment of migraine or cluster headache.
    Type: Grant
    Filed: December 21, 2018
    Date of Patent: August 9, 2022
    Assignees: Taiwan Liposome Co., Ltd, TLC Biopharmaceuticals, Inc.
    Inventors: Keelung Hong, Hao-Wen Kao, Yi-Yu Lin
  • Patent number: 11406597
    Abstract: The disclosure describes a fusogenic liposome-coated porous silicon nanoparticles for high loading efficiency of anionic payloads (small molecules, dyes, nucleic acids), and for non-endocytic delivery of hydrophilic and lipophilic payloads by membrane fusion. The liposome coating can be further modified with targeting peptides or antibodies via covalent binding chemistry between the ligands and functionalized poly(ethylene glycol). The surface moieties can be transferred to the cellular membrane surface by fusogenic uptake. The composition of the disclosure can be applied in the treatment of diseases by delivering entrapped/encapsulated payloads.
    Type: Grant
    Filed: July 6, 2020
    Date of Patent: August 9, 2022
    Assignee: The Regents of the University of California
    Inventors: Michael J. Sailor, Byungji Kim, Jinyoung Kang
  • Patent number: 11400049
    Abstract: The disclosure relates generally to compositions comprising pegylated liposomal formulations of apelin for the treatment of cardiovascular-related diseases.
    Type: Grant
    Filed: October 19, 2017
    Date of Patent: August 2, 2022
    Assignee: Avive, Inc.
    Inventor: Jayakumar Rajadas
  • Patent number: 11389408
    Abstract: The present invention relates to a method for preparing a protocell in form of a giant unilamellar vesicle, which comprises the following steps: a) providing a water-based droplet encapsulated by an outer polymer shell, which borders the inner space of the droplet, wherein the droplet has a maximum dimension of 0.5 ?m to 1,000 ?m, wherein the inner space of the droplet contains at least one lipid, b) transforming the lipid content of the droplet into a lipid bilayer which is arranged at and covers the inner surface of the polymer shell and oil phase in order to form a polymer shell-stabilized giant unilamellar vesicle, c) optionally incorporating one or more proteins and/or nuclei into the polymer shell-stabilized giant unilamellar vesicle provided in step b) and d) optionally removing the polymer shell and oil phase from the polymer shell-stabilized giant unilamellar vesicle and optionally transferring it from the oil to the water phase.
    Type: Grant
    Filed: June 6, 2018
    Date of Patent: July 19, 2022
    Inventors: Joachim P. Spatz, Lucia T. Benk, Johannes Patrick Frohnmayer, Barbara Haller, Jan-Willi Janiesch, Yilia Plazman, Marian Weiss
  • Patent number: 11389405
    Abstract: Disclosed herein is a particle containing an inner liposomal vesicle (ILV) encapsulating a therapeutic agent; an outer liposomal vesicle (OLV) encapsulating the ILV; a membrane fusion-promoting agent; and a pH-altering agent. Also disclosed are methods of delivering a therapeutic agent to a subject comprising: a) providing a herein disclosed particle b) triggering ILV and OLV fusion; and c) releasing the therapeutic agent outside of the OLV. Also disclosed are methods for treating a disease in a subject in need thereof comprising: administering to a subject a herein disclosed particle. Also disclosed are methods to release insulin to an environment comprising increased glucose levels, the method comprising exposing to the environment a herein disclosed particle.
    Type: Grant
    Filed: September 17, 2018
    Date of Patent: July 19, 2022
    Assignee: North Carolina State University
    Inventors: Zhen Gu, Zhaowei Chen
  • Patent number: 11376218
    Abstract: The invention relates to a method for preparing transmembrane pH-gradient vesicles. This method includes the following steps: a) preparing vesicles made from at least one matrix substance in an aqueous medium having an osmolarity of not more than 200 mOsm/l. The matrix substance is chosen from the group consisting of amphiphilic lipids and amphiphilic block copolymers, b) transferring the vesicles into a basic or acidic buffer having an osmolarity being at least 200 mOsm/l higher than the osmolarity of the aqueous medium of step a) to apply an osmotic shock to the vesicles and to obtain buffer-filled vesicles and c) diluting a mixture of the aqueous medium and the basic or acidic buffer containing the buffer-filled vesicles by adding a neutralizing solution to obtain transmembrane pH-gradient vesicles suspended in a suspension buffer, which differs from the basic or acidic buffer in pH value.
    Type: Grant
    Filed: May 3, 2016
    Date of Patent: July 5, 2022
    Assignee: Versantis AG
    Inventors: Jean-Christophe Leroux, Vincent Forster, Valentina Agostoni
  • Patent number: 11344552
    Abstract: Combination therapy regimens including liposomal irinotecan, oxaliplatin and 5-fluorouracil are useful in the treatment of pancreatic cancer, including treatment of patients diagnosed with previously untreated metastatic adenocarcinoma of the pancreas. The combination therapy can include the administration of liposomal irinotecan, oxaliplatin, leucovorin and 5-fluorouracil once every two weeks.
    Type: Grant
    Filed: November 10, 2017
    Date of Patent: May 31, 2022
    Inventors: Eliel Bayever, Sarah F. Blanchette, Jonathan Basil Fitzgerald, Daniel F. Gaddy, Bart S. Hendriks, Ashish Kalra, Helen Lee
  • Patent number: 11344490
    Abstract: The present invention provides a method for removing a tattoo in a region of skin the method comprises administering to a least a portion of the tattoo a composition comprising an effective amount of a bisphosphonate and at least one pharmaceutically acceptable excipient to at least cause fading of the tattoo in said region.
    Type: Grant
    Filed: September 7, 2018
    Date of Patent: May 31, 2022
    Assignee: Dalhousie University
    Inventor: Alec Guy Falkenham
  • Patent number: 11344497
    Abstract: An aqueous, intra-oral, nanoemulsion blend is provided that enhances mitochondrial performance in mammals when orally administered. The blend includes at least two different monolayer surfactant bound particle components and at least one bilayer water-core liposome component. The blend optionally may include a micelle.
    Type: Grant
    Filed: December 10, 2018
    Date of Patent: May 31, 2022
    Assignee: Quicksilver Scientific, Inc.
    Inventors: Christopher W. Shade, Steven Tieu
  • Patent number: 11337931
    Abstract: A targeting nanoparticle composition and method of treatment for diseases associated with major basement membrane components of blood vessels accessible from blood stream is presented. The composition includes pegylated perfluorocarbon nanoparticles having a targeting ligand attached that targets the basement membrane components, specifically collagen IV. The targeted nanoparticles may contain at least one pharmaceutically active agent capable of treating a glomerular disease such as lupus nephritis.
    Type: Grant
    Filed: November 17, 2020
    Date of Patent: May 24, 2022
    Assignee: University of South Florida
    Inventors: Ruisheng Liu, Samuel A. Wickline, Jin Wei, Hua Pan, Jie Zhang
  • Patent number: 11331272
    Abstract: Hyperstable liposome comprising an anti-mitotic agent, one or more anions and one or more cations entrapped in the inner milieu, wherein the entrapped anti-mitotic drug is released at a slow rate that is less than 0.6% in 12 hours or less than 5% in 8 hours when the liposomes are suspended in 600 mM sucrose. These liposomes are useful in the treatment of cancer. In particular, HEPC:Chol:DSPE-PEG2000 (50:45:5) liposomes comprising BI 2536 and citrate:phosphate in a ratio of 1:3.
    Type: Grant
    Filed: January 17, 2018
    Date of Patent: May 17, 2022
    Assignee: Temasek Life Sciences Laboratory Limited
    Inventors: Chang Zhi Adrian Ng, Shen-Yi Ian Cheong
  • Patent number: 11324698
    Abstract: The application disclosure provides a sterically stabilized liposome carrier encapsulating a selected drug for the aerosol delivery of the drug effectual in the treatment of a mammal, a composition containing the sterically stabilized liposome carrier and the selected drug effective for the treatment of airway hypersensitivity and inflammation such as of the lungs of a mammal as an aerosol, and a method of treatment using the composition. The composition disclosed herein provides effective treatment for the longer of a period of time at least twice as long as the selected drug alone or up to at least one week.
    Type: Grant
    Filed: April 23, 2020
    Date of Patent: May 10, 2022
    Assignee: VGSK Technologies, Inc.
    Inventors: Kameswari S. Konduri, Sandhya N. Nandedkar, Nejat Duzgunes, Pattisapu Ram Jogi Gangadharam
  • Patent number: 11318131
    Abstract: Novel therapies for the treatment of small cell lung cancer (SCLC) include the administration of an antineoplastic therapy consisting of liposomal irinotecan administered once every two weeks, optionally including the administration of other non-antineoplastic agents to the patient such as the administration of a corticosteroid and an anti-emetic to the patient prior to the administration of the irinotecan liposome.
    Type: Grant
    Filed: May 17, 2017
    Date of Patent: May 3, 2022
    Inventors: Bambang Adiwijaya, Jonathan Basil Fitzgerald, Helen Lee